UCB0942 + UCB0942 + Placebo

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Highly Drug-resistant Focal Epilepsy

Conditions

Highly Drug-resistant Focal Epilepsy

Trial Timeline

Jul 1, 2015 → Jul 1, 2017

NCT ID

NCT02495844

About UCB0942 + UCB0942 + Placebo

UCB0942 + UCB0942 + Placebo is a phase 2 stage product being developed by UCB for Highly Drug-resistant Focal Epilepsy. The current trial status is completed. This product is registered under clinical trial identifier NCT02495844. Target conditions include Highly Drug-resistant Focal Epilepsy.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02495844	Phase 2	Completed	Jul 1, 2015	Jul 1, 2017	Highly Drug-resistant Focal Epilepsy

Competing Products

5 competing products in Highly Drug-resistant Focal Epilepsy

See all competitors

Product	Company	Stage	Hype Score
everolimus + low-dose tacrolimus	Novartis	Phase 2	35
Inebilizumab + VIB4920 + Inebilzumab+VIB4920	Amgen	Phase 2	27
carfilzomib + belatacept	Bristol Myers Squibb	Phase 1/2	36
daratumumab + belatacept	Bristol Myers Squibb	Phase 1/2	36
UCB0942	UCB	Phase 2	27